We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Serum Pepsinogen Validated for Atrophic Gastritis Diagnosis

By LabMedica International staff writers
Posted on 01 Aug 2017
Atrophic gastritis (AG) and intestinal metaplasia (IM) are well-recognized as high-risk conditions for developing gastric cancer (GC), and both have been identified as the precancerous lesions, but the clinical symptoms of AG are not specific.

The early detection of precancerous lesions of GC in general population and following up with the condition are important considerations for reducing mortality, increasing survival rates, and improving quality of life. More...
The measurement of pepsinogen (PG) as a screening test for chronic atrophic gastritis (AG) in health check-up populations has been suggested.

Physicians at the Second Affiliated Hospital of Zhejiang University (Hangzhou, China) enrolled subjects, who received consecutive regular health check-up from January 2014 to June 2015. The patients included in this study ranged from 20 to 70 years in age. All the participants underwent gastroendoscopy and pathology tests, serum PG test, 13C–urea breath test or Helicobacter pylori (Hp) serological current infection marker rapid test in one day.

Serum PG levels were assayed by chemiluminescent microparticle immunoassay method using Abbott ARCHITECT Pepsinogen I and II Reagent Kit. Each subject was also examined with 13C–urea breath test or Hp serological current infection marker rapid test. Hp infection was determined based on the results of 13C–urea breath test or H. pylori serological rapid current infection marker test, combined with the pathological screening.

The scientists found the total Hp infection rate was 40% and based on pathology, the 996 participants were divided into three groups: non-atrophic (NAG), mild-moderate atrophic (MAG), and severe atrophic (SAG). Compared with NAG and MAG groups, the Pepsinogen I (PGI)/ Pepsinogen II (PGII) ratio (PGR) decreased significantly in SAG group. PGI and PGII levels were significantly elevated in Hp-positive group, while the PGR was markedly decreased. When MAG and SAG groups were combined and compared with NAG group, the best cutoff value for atrophy diagnosis was PGI ≤50.3 ng/mL; the cutoff value in Hp-negative group was absolutely higher than in Hp-positive group. When NAG and MAG groups were combined and compared with the SAG group, the best cutoff value for diagnosis of severe atrophy was at PGR ≤4.28. The cutoff values in Hp-negative and Hp-positive groups were calculated at PGR ≤6.28 and ≤4.28, respectively.

The authors concluded that serum pepsinogens are a cost effective screening method in the identification of patients with AG, especially severe AG, which are precancerous lesions of GC. The use of different cutoff values of PG for Hp-negative and Hp-positive groups may offer greater efficacy in the diagnosis of AG. The study was published on July 20, 2017, in the journal BMC Gastroenterology.

Related Links:
Second Affiliated Hospital of Zhejiang University


New
Gold Member
Automatic Hematology Analyzer
DH-800 Series
Collection and Transport System
PurSafe Plus®
New
Gold Member
Collection and Transport System
PurSafe Plus®
Gel Cards
DG Gel Cards
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: The CloneSeq-SV approach can allow researchers to study how cells within high-grade serous ovarian cancer change over time (Photo courtesy of MSK)

Blood Test Tracks Treatment Resistance in High-Grade Serous Ovarian Cancer

High-grade serous ovarian cancer (HGSOC) is often diagnosed at an advanced stage because it spreads microscopically throughout the abdomen, and although initial surgery and chemotherapy can work, most... Read more

Industry

view channel
Image: The collaboration aims to improve access to Hb variant testing with the Gazelle POC diagnostic platform (Photo courtesy of Hemex Health)

Terumo BCT and Hemex Health Collaborate to Improve Access to Testing for Hemoglobin Disorders

Millions of people worldwide living with sickle cell disease and other hemoglobin disorders experience delayed diagnosis and limited access to effective care, particularly in regions where testing is scarce.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.